Skip to main content

Advertisement

Table 2 Baseline predictors and 5-year outcomes

From: Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

  VR % P-value HBeAg loss % P-value HBeAg seroconversion % P-value
ALT≥5 × ULN 75.0% 0.035 43.9% 0.017 37.9% 0.035
ALT < 5 × ULN 43.8%   13.8%   13.8%  
HBeAg < 800 s/co 88.9% 0.027 77.8% 0.045 27.8% 0.831
HBeAg≥800 s/co 47.6%   38.0%   19.0%  
HBsAg < 5000 IU/ml 80.0% 0.132 80.0% 0.026 27.8% 0.200
HBsAg≥ 5000 IU/ml 59.3%   48.1%   24.1%  
HBV DNA < 9 log10 copies/ml 71.9% 0.494 61.8% 0.621 26.5% 0.702
HBV DNA≥ 9 log10copies/ml 69.2%   53.9%   15.4%